Searching for 3 ml semaglutide? Here is what that figure actually means

Why do all Wegovy pens contain 3 ml, regardless of the dose?

The 3 ml fill is a manufacturing and device standard, not a clinical measurement. Novo Nordisk designed the Wegovy KwikPen to hold 3 ml of liquid, which provides four weekly injections before the pen is empty. What varies across the dose range is the concentration of semaglutide dissolved in that 3 ml. A 0.25 mg weekly pen contains a much lower concentration per ml than a 2.4 mg weekly pen, even though both hold exactly the same total volume.

This is a common point of confusion, and understandably so. If you have seen a product listing or clinic description referring to "3 ml semaglutide", it is almost certainly describing the pen format rather than a specific dose, and our guide to 5 ml semaglutide shows how other fill volumes follow the same logic in a different format. For practical purposes, the number that matters to your treatment is the dose in milligrams per week, which your prescriber sets and adjusts over time. The full semaglutide overview on our site covers how the medicine works in more detail.

Storing the pen correctly matters too. Wegovy pens should be kept refrigerated between 2°C and 8°C until you are ready to use one. The Patient Information Leaflet that comes with your pen gives the exact guidance on how long it can stay at room temperature, always follow that rather than any general figure you read online.

What are the actual dose steps, and how does titration work?

Because the 3 ml volume is fixed, the titration schedule moves through different concentration pens rather than adjusting how much liquid you inject. Treatment starts at 0.25 mg per week for the first four weeks, a tolerability stage designed to let your body adjust, particularly to the gastrointestinal effects that are common early on. From there, doses increase roughly every four weeks: 0.5 mg, then 1.0 mg, then 1.7 mg, and finally the standard 2.4 mg maintenance dose.

The MHRA's April 2026 approval of a single-dose 7.2 mg pen (confirmed on the GOV.UK announcement) extends the ceiling further for eligible patients. That higher dose is for adults with a BMI of 30 or above and is reached only after working through the lower rungs under clinical supervision. The starting dose remains 0.25 mg regardless of which maintenance dose you ultimately reach.

Your prescriber decides when, or whether, to move you up. Skipping steps is not recommended, and the timing is not something to adjust on your own. If you are curious about how a specific dose looks in practice, our page on the 1.25 mg concentration gives a worked example of how concentration and volume relate at one point in the schedule.

Does the 3 ml format affect how you use or carry the pen?

The pen size is compact enough for everyday life, but the refrigeration requirement does need planning. If you are travelling, booking a holiday around a prescription delivery date is something a lot of patients think about, worth factoring in whether your order will arrive before you leave, rather than discovering a timing clash the week of departure. Our pharmacy dispatches next-working-day via DPD once a prescriber has approved your order, which helps with predictability.

For travel, the pen can be kept at room temperature for a limited period per the leaflet's guidance. It travels in hand luggage, though you will want to carry your prescription or dispensing label as evidence for airport security. Needles should be disposed of in a sharps container rather than in general waste.

The pen is pre-filled and pre-set to the prescribed dose, so there is no drawing up of liquid or manual measurement. Each weekly injection delivers the same volume of liquid at the concentration printed on the label. What changes between pens as you titrate is the pen you are given, not anything you adjust yourself. Our Wegovy treatment page covers the practical side of using the pen from week one.

Who can be prescribed Wegovy, and what does clinical assessment involve?

Wegovy's UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 where at least one weight-related health condition is present, things like high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not determine suitability; a prescriber looks at the whole picture, including your medical history, current medicines and any conditions that would make treatment unsuitable.

The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. Those figures come from a closely monitored clinical setting alongside lifestyle support, and individual results vary. Wegovy is not assessed or licensed for quick or cosmetic weight loss.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance TA875, but waiting lists can be long and the criteria are specific. Private treatment through a regulated pharmacy is an option for people who do not meet NHS thresholds or prefer not to wait. If you want to understand how private costs compare across the market, our Wegovy pricing guide sets out the context honestly. For a broader look at licensed weight-loss treatments, the weight-loss treatment overview is a useful starting point. The 2 ml semaglutide page addresses another volume query that comes up alongside this one.

If you think Wegovy could be right for you, a clinical assessment is the next step. At nume, a GPhC-registered Independent Prescriber reads every consultation personally. Check your eligibility by starting your free consultation.